Clinical Trials Logo

Clinical Trial Summary

Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.


Clinical Trial Description

Following a presumed primary EBV infection, a 19 year old female patient rapidly suffered systemic inflammatory response, hemophagocytosis, multi-organ failure and evidence of EBV+ T-cell lymphoma. The patient was aggressively treated and responded to SMILE-based chemotherapy. Once complete response was ascertained by PET imaging, the patient underwent myeloablative HLA-matched unrelated allogeneic stem cell transplantation (cyclophosphamide 60mg/Kg, total body irradiation - 12Gy with anti-thymocyte globulin). The stem cell donor had a positive serology for EBV (IgG). The patient's EBV titer was weakly positive at the time of transplantation. A decision was made to offer consolidative treatment consisting of donor-derived ex vivo expanded EBV-reactive T cells following transplantation. A EBV-specific T-cell line was manufactured from a portion of the cryopreserved G-CSF mobilized peripheral graft after appropriate authorizations were obtained. The patient suffered a severe episode of intestinal graft-versus-host disease early following transplantation but received a first dose of EBV-reactive T cells (20x10e6 T cells/meter square of body surface area 5 months post-transplantation ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06391814
Study type Interventional
Source Ciusss de L'Est de l'Île de Montréal
Contact Jean-Sébastien Delisle, MD, PhD
Phone 514-252-3400
Email js.delisle@umontreal.ca
Status Recruiting
Phase N/A
Start date January 16, 2024
Completion date April 5, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05011058 - An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas Phase 2
Active, not recruiting NCT01823718 - Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes Phase 1